The final day of the 8th Advanced Breast Cancer International Consensus Conference, ABC8 2025 Day 3 marked the culmination of three transformative days of scientific dialogue, patient advocacy, and collective purpose. On Saturday, 8 November 2025, the spotlight turned to the Consensus Sessions the defining heart of the ABC meetings, where months of evidence review and expert discussion converge into updated global recommendations for the management of advanced and metastatic breast cancer.Chaired by the ABC8 Scientific Committee, these sessions gathered more than 50 experts and patient advocates representing all continents. Topics covered included optimal treatment sequencing, integration of biomarkers such as ESR1 mutations and PIK3CA testing, management of brain and leptomeningeal metastases, and supportive care for long-term survivors. The committee also addressed real-world barriers to access reaffirming that guidelines must serve not only high-resource settings but also regions with limited infrastructure.At 11:00, Rania Azmi, Chair of the ABC Patient Advocacy Committee, delivered a passionate report emphasizing that advocacy and science must move forward hand in hand. She called for universal access to palliative care, reduction of financial toxicity, and the inclusion of patients in clinical trial design, reminding the audience that “patients are not endpoints of research thay are its partners.” Her remarks received a standing ovation.
The second consensus session finalized recommendations on emerging systemic therapies, including antibody-drug conjugates (adcs), novel endocrine agents, and immunotherapy combinations highlighting both opportunities and unmet needs in ensuring equitable availability across countries.
As the conference drew to a close, Prof. Fatima Cardoso reflected on a decade of unified progress under the ABC Global Alliance, announcing that the newly ratified ABC Global Charter 2025-2035 will guide the movement’s vision for the next ten years. Her closing message captured the essence of ABC8:
“Our mission is not only to extend life but to ensure that every person with advanced breast cancer can live with dignity, meaning, and hope – wherever they are in the world.”
Applause filled the Centro de Congressos de Lisboa as participants rose together researchers, clinicians, and patient advocates united by one purpose: to continue transforming evidence into empathy, and science into survival.
A Look Back: The Journey to Consensus day 2: Science, Systems, and Survivorship Toward Integrated Progress
Table of Contents
As the foundation for the final consensus, Day 2 explored the intersection of biology, systemic therapy, and global health equity. The morning session on brain and leptomeningeal metastases, chaired by L
ABC8 2025: A Decade of Progress, Unity, and Vision in Advanced Breast Cancer Care
The Advanced Breast Cancer 8th International Congress (ABC8), held recently, concluded with a resounding message of hope, progress, and collaborative spirit in the fight against advanced breast cancer. The conference, a pivotal event for researchers, clinicians, advocates, and survivors, highlighted a decade of advancements and reaffirmed the commitment to achieving equity in access to care. ABC8 2025 wasn’t just a scientific meeting; it was a powerful presentation of unity, emphasizing that every contribution, conversation, and compassionate act moves the world closer to better outcomes for those living with advanced breast cancer.
Key Highlights from ABC8 2025
The congress showcased breakthroughs in understanding the molecular complexities of advanced breast cancer,leading to more targeted and effective therapies. Researchers presented findings on overcoming resistance mechanisms, identifying novel biomarkers for treatment selection, and exploring innovative approaches like immunotherapy and antibody-drug conjugates.
Beyond the scientific advancements, ABC8 2025 placed critically important emphasis on the patient experiance and the critical role of advocacy. Survivors shared their stories, highlighting the challenges they face and advocating for policies that improve access to care, reduce disparities, and support research. This year’s conference underscored the importance of a patient-centered approach, integrating the perspectives of those directly affected by the disease into research and clinical practice.
Larry norton Receives Lifetime Achievement Award
A highlight of the conference was the presentation of the ABC8 Lifetime Achievement Award for Excellence in Oncology to dr. Larry Norton. OncoDaily reported on the well-deserved recognition of Dr. Norton’s decades of groundbreaking contributions to breast cancer research and treatment. Dr. Norton is a renowned oncologist and researcher known for his work on de-escalation strategies in breast cancer treatment, aiming to reduce needless toxicity while maintaining efficacy.His advocacy for individualized treatment plans and his commitment to improving the lives of patients have made him a leader in the field.
The Growing Importance of Molecular resistance Research
A significant focus of ABC8 2025 was the ongoing research into mechanisms of resistance to therapies. Understanding why cancers become resistant is crucial for developing strategies to overcome this challenge. Researchers presented data on:
* Genomic profiling: Identifying specific genetic mutations that drive resistance.
* Microenvironment interactions: Investigating how the tumor microenvironment contributes to treatment failure.
* Novel drug targets: Discovering new molecular targets that can be exploited to restore sensitivity to therapies.
These advancements are paving the way for more personalized treatment approaches, tailoring therapies to the unique characteristics of each patient’s cancer.
advocacy and policy Reform: A Central theme
ABC8 2025 demonstrated a strong commitment to translating scientific discoveries into tangible improvements in patient care. Advocacy groups played a vital role in the conference,raising awareness about critical issues such as:
* Access to affordable medications: Ensuring that all patients have access to the treatments they need,nonetheless of their socioeconomic status.
* Clinical trial diversity: Increasing representation of diverse populations in clinical trials to ensure that research findings are applicable to all patients.
* Support services for survivors: Providing comprehensive support services to address the physical, emotional, and financial challenges faced by survivors of advanced breast cancer.
Looking Ahead: A Future Driven by Collaboration
ABC8 2025 served as a powerful reminder that progress in advanced breast cancer care requires a collaborative effort.From researchers decoding molecular resistance to survivors leading advocacy and policy reform,the conference exemplified the power of unity. As the field moves forward, continued collaboration, innovation, and a steadfast commitment to equity will be essential to achieving the ultimate goal: a world where advanced breast cancer is no longer a life-limiting diagnosis.
Source: OncoDaily – Larry Norton Receives the ABC8 Lifetime Achievement Award